Item request has been placed!
×
Item request cannot be made.
×

Processing Request
IQGAP3 activates Hedgehog signaling to confer stemness and metastasis via up-regulating GLI1 in lung cancer.
Item request has been placed!
×
Item request cannot be made.
×

Processing Request
- Additional Information
- Source:
Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
- Publication Information:
Original Publication: London : Nature Publishing Group, copyright 2011-
- Subject Terms:
- Abstract:
Lung cancer ranks as the most prevalent malignant neoplasm worldwide, contributing significantly to cancer-related mortality. Stemness is a well-recognized factor underlying radiotherapy resistance, recurrence and metastasis in non-small-cell lung cancer (NSCLC) patients. Our prior investigations have established the role of IQ motif containing GTPase-activating protein 3 (IQGAP3) in mediating radiotherapy resistance in lung cancer, but its impact on lung cancer stemness remains unexplored. Our bioinformatics analysis results revealed a significant correlation between IQGAP3 and lung cancer stemness. Moreover, we found that IQGAP3 depletion in lung cancer cells resulted in reduced migration, invasion and sphere-forming capabilities. Through RNA sequencing, we identified GLI1 as a pivotal downstream effector of IQGAP3. The knockdown of IQGAP3 led to the downregulation of GLI1 mRNA and protein levels, which impeded the activation of the Hedgehog-GLI1 signaling pathway. Further, our results also indicated that GLI1 is the primary effector mediating IQGAP3's biological functions in lung cancer. These findings elucidate the role of IQGAP3 in promoting lung cancer stemness and metastasis through the Hedgehog pathway, facilitated by GLI1, highlighting the potential of IQGAP3 as a promising therapeutic target for lung cancer treatment.
Competing Interests: Declarations. Ethics approval and consent to participate: The present study was approved by the Ethics Committee of Union Hospital of Huazhong University of Science and Technology. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
- References:
Pharmacol Ther. 2016 Feb;158:71-90. (PMID: 26706243)
Semin Cancer Biol. 2018 Oct;52(Pt 1):103-109. (PMID: 29183778)
Oncol Lett. 2020 Aug;20(2):1179-1192. (PMID: 32724358)
Mol Cancer. 2017 Feb 16;16(1):41. (PMID: 28209166)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
PLoS One. 2014 May 21;9(5):e97578. (PMID: 24849319)
Semin Cancer Biol. 2015 Apr;31:43-51. (PMID: 25153354)
Onco Targets Ther. 2020 Aug 20;13:8299-8311. (PMID: 32903879)
Semin Cancer Biol. 2020 Feb;60:148-156. (PMID: 31521746)
Cell Stem Cell. 2015 Mar 5;16(3):225-38. (PMID: 25748930)
Cancer Lett. 2020 Nov 28;493:254-265. (PMID: 32896617)
Theranostics. 2020 Feb 10;10(7):3083-3098. (PMID: 32194856)
J Clin Invest. 2019 Feb 1;129(2):465-475. (PMID: 30707108)
Nat Rev Mol Cell Biol. 2023 Sep;24(9):668-687. (PMID: 36932157)
Cancer Cell. 2019 Mar 18;35(3):347-367. (PMID: 30889378)
J Exp Clin Cancer Res. 2014 Apr 24;33:34. (PMID: 24758269)
Clin Cancer Res. 2014 Mar 15;20(6):1566-75. (PMID: 24423612)
Cell Death Dis. 2024 Jan 16;15(1):56. (PMID: 38225225)
Nat Rev Mol Cell Biol. 2013 Jul;14(7):416-29. (PMID: 23719536)
J Transl Med. 2017 Aug 15;15(1):176. (PMID: 28810875)
Cells. 2020 Apr 06;9(4):. (PMID: 32268506)
Gut. 2021 Oct;70(10):1833-1846. (PMID: 33293280)
Cells. 2020 Sep 17;9(9):. (PMID: 32957513)
Mol Aspects Med. 2014 Oct;39:50-60. (PMID: 24016594)
Clin Cancer Res. 2015 Feb 1;21(3):505-13. (PMID: 25646180)
Biomolecules. 2020 Aug 17;10(8):. (PMID: 32824461)
Nature. 2018 Jan 24;553(7689):446-454. (PMID: 29364287)
Cell Commun Signal. 2019 Dec 26;17(1):172. (PMID: 31878932)
Cancer Commun (Lond). 2022 Oct;42(10):937-970. (PMID: 36075878)
Nat Rev Clin Oncol. 2015 Aug;12(8):445-64. (PMID: 25850553)
Dev Cell. 2008 Dec;15(6):801-12. (PMID: 19081070)
Mol Cancer. 2016 Mar 18;15:24. (PMID: 26988232)
J Exp Clin Cancer Res. 2024 Mar 16;43(1):83. (PMID: 38493151)
Nat Chem Biol. 2020 Dec;16(12):1303-1313. (PMID: 33199907)
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3196-201. (PMID: 19218434)
Nat Rev Cancer. 2019 Mar;19(3):133-150. (PMID: 30755690)
iScience. 2022 Sep 23;25(10):105194. (PMID: 36217548)
- Grant Information:
82073179 National Natural Science Foundation of China; 82202953 National Natural Science Foundation of China
- Contributed Indexing:
Keywords: GLI1; Hedgehog pathway; IQGAP3; Lung cancer; Stemness
- Accession Number:
0 (Zinc Finger Protein GLI1)
0 (GLI1 protein, human)
0 (Hedgehog Proteins)
0 (IQGAP3 protein, human)
0 (ras GTPase-Activating Proteins)
0 (GTPase-Activating Proteins)
- Publication Date:
Date Created: 20241229 Date Completed: 20241229 Latest Revision: 20250104
- Publication Date:
20250114
- Accession Number:
PMC11682282
- Accession Number:
10.1038/s41598-024-82793-x
- Accession Number:
39732803
No Comments.